Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 4;14(5):1058-1063.
doi: 10.1080/21645515.2017.1381810. Epub 2017 Nov 17.

Impact of meningococcal group B OMV vaccines, beyond their brief

Helen Petousis-Harris  1
Affiliations

Impact of meningococcal group B OMV vaccines, beyond their brief

Helen Petousis-Harris. Hum Vaccin Immunother. .

Abstract

Meningococcal group B outer membrane vesicle vaccines have been used widely in Cuba, New Zealand, and Brazil. They are immunogenic and initially assessed largely by their ability to induce serum bactericidal activity. Measures of efficacy indicate good protection against homologous strains in older children and adults. Effectiveness appears broader than predicted by immunogenicity and efficacy studies. The recent discovery that meningococcal group B OMVs may protect against the related Neisseria species N.gonorrhoeae suggests more to these interesting antigen collections than meets the eye. Currently there are two OMV-containing group B vaccines available, the new recombinant protein-based Bexsero® developed by Novartis and VA-MENGOC-BC® developed by the Finlay institute in Cuba. Also, a third group B vaccine based on two recombinant factor H binding proteins (Trumenba®, Pfizer), has recently been licenced but it does not include OMV. This commentary explores the population impact that group B OMV vaccines have had on meningococcal and gonorrhoea diseases. Given the heterologous effect against diverse strains of the meningococcus observed in older children and adults, and recent evidence to suggest moderate protection against gonorrhoea, there may be a role for these vaccines in programmes targeting adolescents and groups high at risk for both meningococcal disease and gonorrhoea.

Keywords: OMV; gonorrhoea, MeNZB; meningococcal group B; outer membrane vesicle vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Gonorrhoea rates in selected regions, 1998–2014.
See this image and copyright information in PMC

Comment in

References

    1. Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Høiby EA, Bryn K, Oster P, Costantino P, Taha MK, et al.. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine. 2005;23:2202-5. doi:10.1016/j.vaccine.2005.01.058. PMID:15755595 - DOI - PubMed
    1. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al.. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103:10834-9. doi:10.1073/pnas.0603940103. PMID:16825336 - DOI - PMC - PubMed
    1. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med. 2017;14:e1002344. doi:10.1371/journal.pmed.1002344. PMID:28686231 - DOI - PMC - PubMed
    1. Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, Marrazzo JM, Sonder GJB, Schwebke JR, Hoornenborg E, et al.. Sexually transmitted infections: Challenges ahead. Lancet Infect Dis. 2017;17(8):e235-e79. doi:10.1016/S1473-3099(17)30310-9. PMID:28701272 - DOI - PubMed
    1. Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10:995-1007. doi:10.4161/hv.27739. PMID:24500529 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources